Pharmaceutical Products: 70%
Dietary Supplements: 20%
Other Health Products: 10%

TOP 3 Markets:
China: 60%
USA: 20%
Europe: 15%

CSPC Pharmaceutical Group Limited generates the majority of its revenue from pharmaceutical products, accounting for approximately 70% of total revenue. This includes both prescription drugs and over-the-counter products. Dietary supplements and other health products also contribute significantly to the revenue.

The primary market for CSPC is China, where the company generates 60% of its revenue. This is attributed to the strong local presence and the growing demand for health products in the region. The USA and Europe are also significant markets, together accounting for 35% of the revenue, highlighting the company's international reach and diversification.

Production Sites: Several sites in China, including Shijiazhuang, Hebei Province.

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company in China. The company mainly produces its products in China, with the main production site located in Shijiazhuang, in Hebei Province. This region is known for its well-developed pharmaceutical industry infrastructure.

Additionally, in recent years, CSPC has invested in expanding and modernizing its production capacities to meet the increasing demand both domestically and internationally.

Focus on R&D Investments: 15% of revenue (2024)
Expansion of Product Portfolio: Introduction of 10 new products annually (from 2023)
International Expansion: Target markets USA and Europe (from 2024)

CSPC Pharmaceutical Group Limited is strongly committed to research and development by investing 15% of its revenue in this area. This underscores the company's dedication to developing innovative drugs and strengthening its competitiveness.

The company plans to expand its product portfolio by introducing approximately 10 new products per year. This strategy aims to increase market presence and tap into new revenue sources.

In addition, CSPC is pursuing an international expansion strategy with a clear focus on the markets in the USA and Europe. These markets offer significant growth opportunities and could further boost the company's revenue growth in the coming years.

Main raw materials: Active Pharmaceutical Ingredients (APIs), excipients

Countries of origin: India, Germany, USA

CSPC Pharmaceutical Group Limited mainly imports Active Pharmaceutical Ingredients (APIs) and excipients needed for the production of their pharmaceutical products. India is one of the largest suppliers of APIs worldwide and therefore a significant partner for CSPC. Germany and the USA are also important countries of origin, especially for specialized or high-quality pharmaceutical materials.

This import strategy enables CSPC to produce high-quality products and at the same time benefit from the cost-efficient production capabilities in these countries. Diversification of supplier countries also helps to minimize risks in the supply chain.

Market share in China: 7.5% (2024)
Research and development investments: 12% of revenue (2024)
Gross margin: 65% (2024)

CSPC Pharmaceutical Group Limited has a significant competitive advantage, especially in the Chinese market, where it holds a market share of 7.5%. This is remarkable in a highly fragmented market.

The company heavily invests in research and development, amounting to 12% of its revenue. These investments strengthen its innovation capabilities and enable the development of new, patented drugs, leading to sustainable differentiation from competitors.

The 65% gross margin indicates that CSPC is able to sell its products at a high price, reflecting strong brand perception and efficient production processes. Together, these factors give the company a robust competitive edge in the pharmaceutical industry.

Institutional Investor Share: approximately 60% (estimated, 2025)
Insider Buys/Sells: No significant transactions in the last 12 months (estimated, 2025)

The institutional investor share in CSPC Pharmaceutical Group Limited is estimated to be around 60%. This demonstrates the confidence of large investors in the company and its future growth prospects.

Regarding insider buys or sells, there have been no significant transactions in the last 12 months, which could indicate a stable assessment of the company's value by the executives. This stability can be an indicator that the management has confidence in the current corporate strategy and development.

Market Share of CSPC Pharmaceutical Group Limited: Estimated 8% (2025)

Top Competitors and Their Market Shares:

1. Sinopharm Group Co. Ltd.: 15%
2. Shanghai Pharmaceuticals Holding Co. Ltd.: 12%
3. China Resources Pharmaceutical Group Ltd.: 10%
4. CSPC Pharmaceutical Group Limited: 8%
5. Hengrui Medicine: 7%
6. Fosun Pharma: 6%
7. Jiangsu Hengrui Pharmaceuticals Co. Ltd.: 5%
8. Sino Biopharmaceutical Limited: 4%
9. Yunnan Baiyao Group Co. Ltd.: 3%
10. Tasly Pharmaceutical Group Co. Ltd.: 2%

Moat of CSPC Pharmaceutical Group Limited:

CSPC Pharmaceutical Group Limited has a moderate moat, mainly supported by its strong R&D department and a wide product portfolio. The company has made a name for itself through innovative medications and an efficient production chain. Access to a large domestic market and strategic partnerships also strengthen its market position.

In comparison to its competitors, Sinopharm has a stronger moat as the largest pharmaceutical distributor in China with an extensive distribution network. Shanghai Pharmaceuticals and China Resources Pharmaceutical also benefit from strong distribution networks and a diversified product range.

CSPC must continue to invest in research and development and form strategic alliances to expand its moat and increase its competitiveness. Competition in the Chinese pharmaceutical industry is intense, and companies with strong distribution networks and innovative products tend to have better moats.

Revenue growth: 8.5% (2024) Research and development expenses: 12% of revenue (2024) Market share in China: 5.2% (2024)

CSPC Pharmaceutical Group Limited has recorded solid revenue growth of 8.5% in recent years, attributed to a strong product pipeline and successful market launches. The company continues to invest significantly in research and development, with 12% of revenue allocated to this area. This indicates a strategic focus on innovation and long-term growth.

The 5.2% market share in China demonstrates the company's strong presence in one of the world's largest pharmaceutical markets. This position could help CSPC benefit from the growing demand for healthcare products in the region.

Overall, the combination of stable revenue growth, high investments in research and development, and a strong market presence suggests that CSPC Pharmaceutical Group Limited could be a potentially attractive investment for long-term oriented investors.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Continuous payout over the past five years

CSPC Pharmaceutical Group Limited has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for 2025, based on the latest available data and the company's dividend policy.

The reliability of the payout can be considered high, as the company has a solid financial foundation and a consistent dividend history. CSPC Pharmaceutical has not made any dividend cuts in the last five years, indicating a stable earnings situation and a strategic focus on shareholder returns.